Abbv stock price action correlates with sector rotation

ABBV stock price action correlates with sector rotation into defensive healthcare assets. Investors seek stability given macroeconomic uncertainty, providing support for AbbVie’s valuation. AbbVie Inc. (NYSE: ABBV ) ranks among the stocks with low beta that can beat market volatility . On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had reached a settlement that would allow generic Rinvoq to be introduced in April 2037, over four years later than Leerink had previously predicted. AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Featured Stories Five stocks we like better than AbbVie REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today Forget Airlines—These Trucking Stocks Are Shifting Into High Gear Are Penny Stocks a Good Fit for Your Portfolio? QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop Where to Find Earnings Call Transcripts Robinhood Up 12%—Could Prediction Markets Be Its Secret Weapon? This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]. Should You Invest $1,000 in AbbVie Right Now? Before you consider AbbVie, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list. While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here A Guide To High-Short-Interest Stocks MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list. Get This Free Report ABBV stock price volatility remains low relative to peers, appealing to risk-conscious portfolio managers in a choppy market environment.